Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.
Epistemonikos ID: f64ba537e255ae6dcbe54c61832f79f0c4d45c86
First added on: Mar 23, 2020